These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Cdc42 and the guanine nucleotide exchange factors Ect2 and trio mediate Fn14-induced migration and invasion of glioblastoma cells. Fortin SP; Ennis MJ; Schumacher CA; Zylstra-Diegel CR; Williams BO; Ross JT; Winkles JA; Loftus JC; Symons MH; Tran NL Mol Cancer Res; 2012 Jul; 10(7):958-68. PubMed ID: 22571869 [TBL] [Abstract][Full Text] [Related]
6. The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeutics. Perez JG; Tran NL; Rosenblum MG; Schneider CS; Connolly NP; Kim AJ; Woodworth GF; Winkles JA Oncogene; 2016 Apr; 35(17):2145-55. PubMed ID: 26300004 [TBL] [Abstract][Full Text] [Related]
7. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. Tran NL; McDonough WS; Savitch BA; Sawyer TF; Winkles JA; Berens ME J Biol Chem; 2005 Feb; 280(5):3483-92. PubMed ID: 15611130 [TBL] [Abstract][Full Text] [Related]
8. TWEAK/Fn14 promotes pro-inflammatory cytokine secretion in hepatic stellate cells via NF-κB/STAT3 pathways. Wang A; Zhang F; Xu H; Xu M; Cao Y; Wang C; Xu Y; Su M; Zhang M; Zhuge Y Mol Immunol; 2017 Jul; 87():67-75. PubMed ID: 28411440 [TBL] [Abstract][Full Text] [Related]
9. TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance. Loftus JC; Dhruv H; Tuncali S; Kloss J; Yang Z; Schumacher CA; Cao B; Williams BO; Eschbacher JM; Ross JT; Tran NL Mol Cancer Res; 2013 Aug; 11(8):865-74. PubMed ID: 23699535 [TBL] [Abstract][Full Text] [Related]
10. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway. Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149 [TBL] [Abstract][Full Text] [Related]
11. The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling. Peng C; Chen Z; Wang S; Wang HW; Qiu W; Zhao L; Xu R; Luo H; Chen Y; Chen D; You Y; Liu N; Wang H Cancer Res; 2016 Apr; 76(8):2340-53. PubMed ID: 26960975 [TBL] [Abstract][Full Text] [Related]
12. HB-EGF is associated with DNA damage and Mcl-1 turnover in human glioma cell lines treated by Temozolomide. Séry Q; Rabé M; Oliver L; Vallette FM; Gratas C Biochem Biophys Res Commun; 2017 Dec; 493(4):1377-1383. PubMed ID: 28970067 [TBL] [Abstract][Full Text] [Related]
13. TWEAK-independent Fn14 self-association and NF-κB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain. Brown SA; Cheng E; Williams MS; Winkles JA PLoS One; 2013; 8(6):e65248. PubMed ID: 23750247 [TBL] [Abstract][Full Text] [Related]
14. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance. Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522 [TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic TRADD confers a worse prognosis in glioblastoma. Chakraborty S; Li L; Tang H; Xie Y; Puliyappadamba VT; Raisanen J; Burma S; Boothman DA; Cochran B; Wu J; Habib AA Neoplasia; 2013 Aug; 15(8):888-97. PubMed ID: 23908590 [TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioma cell invasion through induction of NF-κB-inducing kinase (NIK) and noncanonical NF-κB signaling. Cherry EM; Lee DW; Jung JU; Sitcheran R Mol Cancer; 2015 Jan; 14(1):9. PubMed ID: 25622756 [TBL] [Abstract][Full Text] [Related]
17. Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis. Dhruv H; Loftus JC; Narang P; Petit JL; Fameree M; Burton J; Tchegho G; Chow D; Yin H; Al-Abed Y; Berens ME; Tran NL; Meurice N J Biol Chem; 2013 Nov; 288(45):32261-32276. PubMed ID: 24056367 [TBL] [Abstract][Full Text] [Related]
18. Histone Deacetylase Inhibitor RGFP109 Overcomes Temozolomide Resistance by Blocking NF-κB-Dependent Transcription in Glioblastoma Cell Lines. Li ZY; Li QZ; Chen L; Chen BD; Wang B; Zhang XJ; Li WP Neurochem Res; 2016 Dec; 41(12):3192-3205. PubMed ID: 27632183 [TBL] [Abstract][Full Text] [Related]
19. p53 upregulated modulator of apoptosis sensitizes drug-resistant U251 glioblastoma stem cells to temozolomide through enhanced apoptosis. Miao W; Liu X; Wang H; Fan Y; Lian S; Yang X; Wang X; Guo G; Li Q; Wang S Mol Med Rep; 2015 Jun; 11(6):4165-73. PubMed ID: 25625235 [TBL] [Abstract][Full Text] [Related]
20. FERMT3 contributes to glioblastoma cell proliferation and chemoresistance to temozolomide through integrin mediated Wnt signaling. Lu C; Cui C; Liu B; Zou S; Song H; Tian H; Zhao J; Li Y Neurosci Lett; 2017 Sep; 657():77-83. PubMed ID: 28778805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]